AmpliPhi Biosciences Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis

Published: Aug 08, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RICHMOND, Va. & SYDNEY & LONDON--(BUSINESS WIRE)--AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment of Pseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held in Olympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news